Exosome banking and adipose banking are often written about as though they were two versions of one service. They are not. One preserves a person’s own tissue under an established federal framework. The other describes isolating and storing a class of particles whose name the research field itself now discourages, and which no regulator has approved as a product.
TLDR Exosome banking is not something Save My Fat offers or plans to offer. MISEV2023, published in February 2024, records that ISEV discourages the word exosome unless subcellular origin can be demonstrated, and recommends the generic term EV instead. FDA states there are currently no FDA-approved exosome products. Whole-cell adipose banking preserves a person’s own tissue, and banking guarantees no eligibility, access, or clinical benefit later.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. FDA states that there are currently no FDA-approved exosome products, and no adipose-derived product has FDA approval for any disease. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Two questions decide this comparison: what the word exosome is allowed to mean, and what regulators have actually approved. The naming is contested inside the field that studies these particles, and the market around them has already drawn a federal safety notification.
The honest comparison is narrow, and it is about rules and words rather than results. Readers new to the subject can start with adipose tissue banking.
Save My Fat does not offer exosome banking and is not planning to. Nothing below previews a service. This piece covers terminology, regulatory status, and where the two ideas diverge.
What Exosome Banking Means, and Why the Term Is Contested
The phrase describes isolating particles released by cells and storing them, usually under the label exosomes. It is contested because the reporting standard used by the field says that label is rarely justified by the evidence behind it.
That standard is MISEV2023, the Minimal Information for Studies of Extracellular Vesicles. It is the current version, published in February 2024 in Journal of Extracellular Vesicles. The MISEV2023 guidelines define the category before anything else.
The definition is plain. The open access full text states that the term extracellular vesicles “refers to particles that are released from cells, are delimited by a lipid bilayer, and cannot replicate on their own.” Nothing in that sentence describes a function or an outcome.
Why MISEV2023 Discourages the Word Exosome
Because exosome names a biogenesis pathway that is difficult to establish. MISEV2023 classifies the term’s status as “Discouraged unless subcellular origin can be demonstrated.” That is a documentation standard, not an opinion about marketing.
The recommendation appears on the ISEV standards page and in the paper: “In general, ISEV recommends use of the generic term ‘EV’ and operational extensions of this term instead of inconsistently defined and sometimes misleading terms such as ‘exosomes’ and ‘ectosomes’ that are associated with biogenesis pathways that are difficult to establish.”
The consequence for any storage claim is concrete. MISEV2023 states that unless subcellular origin can be demonstrated, “it is likely that a broad population of EVs is being studied, not exosomes specifically.” It describes exosomes as a subtype of small EVs, with intraluminal vesicles of endosomes generally smaller than 200 nm in diameter.
How Whole-Cell Adipose Banking Is Regulated
Under 21 CFR Part 1271, the federal rules for human cells, tissues, and cellular and tissue-based products. Whole adipose tissue sits inside that framework as a structural tissue, and processing that alters it moves it toward a different category.
FDA’s July 2020 guidance document says adipose is structural “because it is predominantly composed of adipocytes and surrounding connective tissues that provide cushioning and support to the body.”
Part 1271 sets four criteria at 1271.10(a) that decide whether a product falls under Section 361 alone. Minimal manipulation for structural tissue means processing that does not alter the original relevant characteristics relating to the tissue’s utility for reconstruction, repair, or replacement. Anything failing the criteria, absent an exception, is regulated as a drug, device, or biological product.
That line is not theoretical. The same guidance uses stromal vascular fraction as its example, describing its isolation from adipose tissue as “generally considered more than minimally manipulated because the processing breaks down and eliminates the adipocytes and the surrounding structural components.” Isolation steps carry regulatory weight.
Side by Side: Stored Tissue Versus Isolated Particles
The differences are easiest to see in one view. The table below compares what each idea refers to, how each is named, and where each stands with FDA today. It covers status and rules only, because neither column contains an approved therapy.
| Question | Whole adipose tissue banking | Material marketed as exosomes |
|---|---|---|
| What is preserved | The patient’s own adipose tissue, kept intact | Particles released from cells, delimited by a lipid bilayer, that cannot replicate on their own |
| Naming standard | Defined regulatory terms in 21 CFR Part 1271 | ISEV recommends the generic term EV and discourages exosome unless subcellular origin is demonstrated |
| Route for human use | Section 361 only if all four criteria at 1271.10(a) are met, otherwise a drug, device, or biological product | Regulated as drugs and biological products, subject to premarket review and approval |
| FDA approval status | No adipose-derived product is FDA approved for any disease | There are currently no FDA-approved exosome products |
| Offered by Save My Fat | Connection to a U.S. tissue bank for preservation | Not offered, and not planned |
Read the table as a map of differences, not a ranking of options. Any decision about an individual belongs with a licensed provider, and preserving tissue does not connect anyone to a therapy.
Does Save My Fat Offer Exosome Banking?
No. Save My Fat does not offer exosome banking, does not plan to, and appears here only as the publisher of an education piece.
Save My Fat is a connector that links patients and providers with a U.S. tissue bank. It does not collect, process, store, or treat tissue, and it is not a clinic, not a bank, and not a medical practice.
Preserving tissue also promises nothing about later. Banking does not guarantee eligibility, access, or clinical benefit from any future therapy, trial, or program. Readers wanting the science background can read about extracellular vesicles and ADSCs.
What Current Research and FDA Say About Isolating and Storing EVs
The current reference document stops short of certifying subtypes. MISEV2023 says so directly: “Because of the heterogeneity of EVs, MISEV2023, like MISEV2018, cannot recommend molecular markers of specific EV subtypes.” A marker panel alone cannot confirm what a stored sample is.
FDA is equally direct about status. Its public safety notification on exosome products, issued December 6, 2019, states: “There are currently no FDA-approved exosome products.” It describes reports of serious adverse events among patients in Nebraska who received unapproved products marketed as containing exosomes.
The same notification says such sellers are “taking advantage of patients and flouting federal statutes and FDA regulations.” It also sets the category, stating that exosomes used in humans for diseases and conditions “are regulated as drugs and biological products” subject to premarket review and approval requirements.
Put the facts together before weighing any offer. There are no FDA-approved exosome products, and FDA’s roster of approved cellular therapies lists no adipose-derived product for any disease. This science remains preliminary and early stage, and only a licensed provider can advise on an individual situation.
Frequently Asked Questions
Is exosome banking FDA approved?
No. FDA’s public safety notification states that there are currently no FDA-approved exosome products, and its consumer alert says no regenerative medicine products are approved for orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, or chronic pain. The science is preliminary and early stage, so ask a licensed provider first.
Why do sellers still use the word exosome?
MISEV2023 addresses the science rather than the motive, recommending the generic term EV instead of “inconsistently defined and sometimes misleading terms.” FDA’s patient information page is more pointed: “If you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.”
Can a laboratory prove a stored sample contains exosomes?
Not on markers alone. MISEV2023 cannot recommend molecular markers of specific EV subtypes, and states that unless subcellular origin can be demonstrated, a broad population of EVs is likely being studied rather than exosomes specifically. Ask any seller what subcellular origin evidence exists.
Does banking adipose tissue give access to future vesicle research?
No. Banking today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. Whether stored tissue is ever usable depends on FDA regulatory status, physician guidance, and the pathways available at that time. Isolation steps also change the regulatory category, as 1271.20 makes clear.
Key Takeaways
Exosome banking and whole-cell adipose banking are different ideas with different rules. MISEV2023, published in February 2024, records ISEV’s recommendation to use the generic term EV, discourages exosome unless subcellular origin can be demonstrated, and cannot recommend markers for specific subtypes. FDA states there are currently no FDA-approved exosome products, and no adipose-derived product is FDA approved for any disease. Whole tissue preservation sits under 21 CFR Part 1271, where processing that alters the tissue moves it toward drug and biologic regulation. Save My Fat does not offer exosome banking, and preserving tissue guarantees no future eligibility, access, or benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can review current pricing or ask a question through the contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about adipose tissue banking or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: FDA adipose tissue regulation.
